N-(3.3-Diphenylbutyl)dimethylamin | 46941-62-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3.3-Diphenylbutyl)dimethylamin
• 英文别名: N,N-dimethyl-3,3-diphenylbutan-1-amine
• CAS: 46941-62-2
• 化学式: C₁₈H₂₃N
• 分子量: 253.387
• InChiKey: CXYWSFCXUNNRKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  苯基乙苯 、 2-氯-N,N-二甲基乙胺 生成 N-(3.3-Diphenylbutyl)dimethylamin
  参考文献：
  名称：

  Sindelar,K. et al., Collection of Czechoslovak Chemical Communications, 1972, vol. 37, p. 1195 - 1206

  摘要：

  DOI：

文献信息

• [EN] TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS<br/>[FR] TRIAZOLOBENZAZÉPINES UTILISÉES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA VASOPRESSINE V1A
  申请人：RICHTER GEDEON NYRT

  公开号：WO2019116324A1

  公开（公告）日：2019-06-20

  The present invention relates to 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1]benzazepine derivatives of general formula (I) and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or biologically active metabolites thereof and/or prodrugs thereof and/or solvates thereof and/or hydrates thereof and/or polymorphs thereof which are centrally and/or peripherally acting V1a receptor modulators, particularly V1a receptor antagonists. Additional subject of the present invention is the process for the preparation of the compounds and the intermediates of the preparation process as well. The invention also relates to the pharmaceutical compositions containing the compounds or together with one or more other active substances, as well as to the use in the treatment and/or prophylaxis of a disease or condition associated with V1a receptor function.

  本发明涉及一般式(I)的5,6-二氢-4H-[1,2,4]三唑并[4,3-a][1]苯并蒽啉衍生物和/或其盐和/或其几何异构体和/或其立体异构体和/或其对映异构体和/或其消旋体和/或其非对映异构体和/或其生物活性代谢物和/或其前药和/或其溶剂化合物和/或其水合物和/或其多晶形式，这些化合物是中枢和/或外周作用的V1a受体调节剂，特别是V1a受体拮抗剂。本发明的另一个主题是制备这些化合物的过程以及制备过程的中间体。该发明还涉及含有这些化合物或与一个或多个其他活性物质一起的药物组合物，以及在治疗和/或预防与V1a受体功能相关的疾病或症状中的用途。
• Novel kinase inhibitors
  申请人：Thormann Michael

  公开号：US20120329785A1

  公开（公告）日：2012-12-27

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases.

  本发明涉及式（I）的新型化合物，这些化合物能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗各种疾病。
• Medical implant
  申请人：Boston Scientific Limited

  公开号：EP1803415A1

  公开（公告）日：2007-07-04

  A medical assembly includes an implant and an envelope at least partially enclosing a portion of the implant. The envelope may include a tongue to protect the implant, a scaffold to provide integrity to the envelope, a tab access to ease envelope withdrawal, and/or one or more discontinuities to ease envelope withdrawal.

  一种医疗组件包括植入体和至少部分封闭植入体部分的包膜。包膜可包括保护植入体的舌片、为包膜提供完整性的支架、便于抽出包膜的卡口和/或便于抽出包膜的一个或多个不连续面。
• Scoring balloon with translating scoring wires
  申请人：C.R. Bard, Inc.

  公开号：US10561438B2

  公开（公告）日：2020-02-18

  A device for introduction into a body vessel includes a shaft, a balloon positioned at the distal end of the shaft, a guidewire disposed longitudinally within the shaft to receive a guidewire during use, a balloon disposed at the distal end of the shaft, and longitudinal scoring wires to score a vascular lesion attached to the distal end of the shaft, disposed over the balloon and disposed within the shaft. The proximal ends are welded or otherwise affixed to a spring mounted in the handle. The balloon expands when fluid is delivered to the balloon through the inflation lumen. This expansion pushes the scoring wires against the vascular lesion.

  一种用于导入体内血管的装置包括一个轴、一个位于轴远端部的球囊、一个纵向布置在轴内以便在使用时接收导丝的导丝、一个布置在轴远端部的球囊，以及用于在血管病变处划线的纵向划线，这些划线连接到轴的远端部，布置在球囊上方，并布置在轴内。近端焊接或以其他方式固定到安装在手柄中的弹簧上。当液体通过充气腔输送到球囊时，球囊会膨胀。膨胀会将刻痕线推向血管病变处。
• Immediate/delayed drug delivery
  申请人：DRUG DELIVERY INTERNATIONAL LIMITED

  公开号：US11065205B2

  公开（公告）日：2021-07-20

  In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released immediately following administration and again at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released before sleep and whilst a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for an immediate, followed by a delayed release of drug.

  在一个方面，本发明涉及一种治疗方法，即希望在给药后立即释放活性剂，并在给药后的某个时间点再次释放活性剂。本发明特别适用于在受试者睡眠前和睡眠时释放药剂。本发明除了通过特定的机制治疗某些病症外，还提供了药物立即释放和延迟释放的新配方。